Hepcidin in chronic kidney disease anemia

Area of Science:

• Nephrology
• Hematology
• Biochemistry

Background:

• Chronic kidney disease (CKD) frequently presents with anemia, iron metabolism disturbances, and inflammation.
• Inflammation in CKD elevates hepcidin, a key regulator of iron homeostasis, impacting iron availability.

Purpose of the Study:

• To explore therapeutic strategies for managing anemia in chronic kidney disease patients.
• To investigate the potential of targeting hepcidin to address anemia and iron overload in CKD.

Main Methods:

• Review of current understanding of CKD complications including anemia, inflammation, and iron metabolism.
• Analysis of the role of hepcidin in iron homeostasis within the context of CKD.
• Evaluation of existing treatments for CKD anemia and their associated risks, such as iron overload.

Main Results:

• Hepcidin production is influenced by factors altered in CKD, including hypoxia, erythropoietin, transferrin saturation, and liver iron levels.
• Current treatments for CKD anemia, like erythropoietic agents and iron supplementation, carry risks including iron overload.
• Hepcidin inhibition is identified as a potential strategy to manage CKD anemia and mitigate iron overload.

Conclusions:

• Hepcidin plays a central role in iron regulation and is dysregulated in chronic kidney disease.
• Targeting hepcidin offers a promising therapeutic avenue for managing anemia and preventing iron overload in CKD patients, particularly those on dialysis.